Related Experiment Video
Updated: May 24, 2026
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome
Roger Kurlan1, Giovanna Crespi, Barbara Coffey
1Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey 07902, USA. roger.kurlan@atlantichealth.org
Background:
Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.
Methods:
There was a multicenter randomized, placebo-controlled, double-blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.
Results:
There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (-7.16) and placebo (-7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent- and investigator-scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.
Conclusions:
There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder.
